Abraxis BioScience reportedly hired Goldman Sachs and Lazard to help it decide whether to put itself up for sale. Shares of the company have been increasing since results of a late-stage trial for Abraxane were released showing that the treatment significantly improved the overall response rate of patients with advanced nonsmall-cell lung cancer.

Full Story:

Related Summaries